Opinion
New therapeutic option for the patients with metastatic triple-negative breast cancer: Sacituzumab govitecan-hziy
By Semir Vranic, MD, PhD Bosnian Journal of Basic Medical Sciences Editor in Chief Food and Drug Administration (FDA) has just granted accelerated approval to sacituzumab govitecan-hziy (TRODELVY, Immunomedics, Inc.) for the patients with metastatic […]